Neoadjuvant Darolutamide and Relugolix combination preceding radical prostatectomy for high risk localized and locally advanced prostate cancer: a Phase I/Ib trial
-
Enrollment
This study is currently enrolling. -
Associated Conditions
-
Research Area
Clinical Cancer Research -
Location
-
Principal Investigator
-
Sponsor
AdventHealth CFD
The primary study objective is to determine the safety and feasibility of a new combination of darolutamide and relugolix as neoadjuvant therapy preceding radical prostatectomy (RP) for high-risk prostate cancer (PCa).
Enrollment Form
This study is currently enrolling.